Role of Measurable Residual Disease in Older Adult Acute Myeloid Leukemia

被引：3

作者：

Li, Xueyao ^{[1
]}

Tong, Xiuzhen ^{[1
,2
]}

机构：

[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China

[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hematol, 58 Second Zhongshan Rd, Guangzhou 510080, Peoples R China

来源：

CLINICAL INTERVENTIONS IN AGING | 2023年 / 18卷

关键词：

detection method; risk-stratification marker; postremission decisions; personalized medicine; HEMATOPOIETIC-CELL TRANSPLANTATION; CLONAL HEMATOPOIESIS; PROGNOSTIC RELEVANCE; AML; MUTATIONS; AZACITIDINE; THERAPY; RISK; DECITABINE; MANAGEMENT;

D O I：

10.2147/CIA.S409308

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

There is overwhelming evidence indicating that the use of measurable residual disease (MRD) as a biomarker provides critical prognostic information and that MRD may have a role in directing postremission decisions. There are a variety of assays for MRD assessment, such as multiparameter flow cytometry and molecular assessment of MRD, which present different characteristics in patients older than 60 years of age. Due to multiple reasons related to age, the progress of older adult AML patients is rarely investigated, especially with respect to MRD. In this review, we will clarify the characteristics of different assays for assessing MRD, focusing on its role as a risk-stratification biomarker to predict prognostic information and its role in optimal postremission therapy among older adult AML patients. These characteristics also provide guidance regarding the potential to apply personalized medicine in older adult AML patients.

引用

页码：921 / 931

页数：11

共 66 条

[1] Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia [J].

Aitken, Marisa J. L. ;

Ravandi, Farhad ;

Patel, Keyur P. ;

Short, Nicholas J. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)

[2] Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response [J].

Amatangelo, Michael D. ;

Quek, Lynn ;

Shih, Alan ;

Stein, Eytan M. ;

Roshal, Mikhail ;

David, Muriel D. ;

Marteyn, Benoit ;

Farnoud, Noushin Rahnamay ;

de Botton, Stephane ;

Bernard, Olivier A. ;

Wu, Bin ;

Yen, Katharine E. ;

Tallman, Martin S. ;

Papaemmanuil, Elli ;

Penard-Lacronique, Virginie ;

Thakurta, Anjan ;

Vyas, Paresh ;

Levine, Ross L. .

BLOOD, 2017, 130 (06) :732-741

[3] Age and acute myeloid leukemia [J].

Appelbaum, FR ;

Gundacker, H ;

Head, DR ;

Slovak, ML ;

Willman, CL ;

Godwin, JE ;

Anderson, JE ;

Petersdorf, SH .

BLOOD, 2006, 107 (09) :3481-3485

[4] Incorporating hematopoietic cell transplantation (HCT) into the management of adults aged under 60 years with acute myeloid leukemia (AML) [J].

Appelbaum, Frederick R. .

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2008, 21 (01) :85-92

[5] Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse [J].

Boddu, P. ;

Jorgensen, J. ;

Kantarjian, H. ;

Borthakur, G. ;

Kadia, T. ;

Daver, N. ;

Alvarado, Y. ;

Pemmaraju, N. ;

Bose, P. ;

Naqvi, K. ;

Yilmaz, M. ;

Pierce, S. ;

Brandt, M. ;

DiNardo, C. D. ;

Jabbour, E. J. ;

Konopleva, M. ;

Garcia-Manero, G. ;

Cortes, J. ;

Ravandi, F. .

LEUKEMIA, 2018, 32 (01) :241-244

[6] Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients [J].

Buccisano, F. ;

Maurillo, L. ;

Piciocchi, A. ;

Del Principe, M. I. ;

Sarlo, C. ;

Cefalo, M. ;

Ditto, C. ;

Di Veroli, A. ;

De Santis, G. ;

Consalvo, M. Irno ;

Fraboni, D. ;

Panetta, P. ;

Palomba, P. ;

Attrotto, C. ;

Del Poeta, G. ;

Sconocchia, G. ;

Lo-Coco, F. ;

Amadori, S. ;

Venditti, A. .

ANNALS OF HEMATOLOGY, 2015, 94 (08) :1319-1326

[7] Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia [J].

Buccisano, Francesco ;

Dillon, Richard ;

Freeman, Sylvie D. ;

Venditti, Adriano .

CANCERS, 2018, 10 (07)

[8] Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia [J].

Buccisano, Francesco ;

Maurillo, Luca ;

Del Principe, Maria Ilaria ;

Del Poeta, Giovanni ;

Sconocchia, Giuseppe ;

Lo-Coco, Francesco ;

Arcese, William ;

Amadori, Sergio ;

Venditti, Adriano .

BLOOD, 2012, 119 (02) :332-341

[9] Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study [J].

Cilloni, Daniela ;

Renneville, Aline ;

Hermitte, Fabienne ;

Hills, Robert K. ;

Daly, Sarah ;

Jovanovic, Jelena V. ;

Gottardi, Enrico ;

Fava, Milena ;

Schnittger, Susanne ;

Weiss, Tamara ;

Izzo, Barbara ;

Nomdedeu, Josep ;

van der Heijden, Adrian ;

van der Reijden, Bert A. ;

Jansen, Joop H. ;

van der Velden, Vincent H. J. ;

Ommen, Hans ;

Preudhomme, Claude ;

Saglio, Giuseppe ;

Grimwade, David .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5195-5201

[10] Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis [J].

Corces-Zimmerman, M. R. ;

Majeti, R. .

LEUKEMIA, 2014, 28 (12) :2276-2282

← 1 2 3 4 5 6 7 →